<![CDATA[STALICLA SA. 보도자료 - 뉴스와이어]]>https://www.newswire.co.kr/?md=A10&act=article&no=36623>Tue, 21 Apr 2026 22:13:37 +0900Copyright (c) 2004~2026 Korea Newswire All rights reservedko-KR<![CDATA[STALICLA Awarded EUR 1.7 Million to Lead Computational Drug Repositioning Activities in EU-funded REPO4EU Project]]>https://www.newswire.co.kr/newsRead.php?no=948319Thu, 21 Jul 2022 09:40:00 +0900<![CDATA[스탈리클라, EU가 후원하는 ’REPO4EU’ 프로젝트서 컴퓨터 이용 신약 재창출 프로젝트 주도하기 위해 170만유로 지원받아]]>https://www.newswire.co.kr/newsRead.php?no=948320Thu, 21 Jul 2022 09:40:00 +0900<![CDATA[STALICLA Completes Successful Phase 1b Trials for the First Precision Medicine in Autism Spectrum Disorder]]>https://www.newswire.co.kr/newsRead.php?no=941704Mon, 28 Mar 2022 10:00:00 +0900<![CDATA[스탈리클라, 자폐 스펙트럼 장애 치료 위한 최초의 정밀 의약품 임상 1상 성료]]>https://www.newswire.co.kr/newsRead.php?no=941705Mon, 28 Mar 2022 10:00:00 +0900<![CDATA[STALICLA Translates its Novel Precision Medicine Approach for Autism Spectrum Disorder into Clinical Development with First Patient in Phase 1b Trial of STP1]]>https://www.newswire.co.kr/newsRead.php?no=915749Fri, 11 Dec 2020 12:27:32 +0900